Jarrow Formulas intros omega-3 supplement boasting higher bioavailability
LOS ANGELES — Jarrow Formulas earlier this month launched PhosphOmega, a phospholipid-omega-3 fatty acid complex. According to the company, phospholipid-bound omega-3s have higher bioavailability than ordinary fish oils.
“The omega-3s in seafood are consumed both as phospholipids and triglycerides,” Jarrow Formulas marketing director Rory Lipsky said. “For example, 80% of the fatty acids in trout are phospholipids and 20% are triglycerides. PhosphOmega provides omega-3s in both the triglyceride and phospholipid forms.”
Krill oil has become a more well-known and popular source of omega-3 fatty acids because 40% of the omega-3s are phospholipid-bound, Lipsky noted.
Sam’s Club to host men’s health screenings
BENTONVILLE, Ark. — Sam’s Club is marking Men’s Health Month in June by offering free men’s health screenings at its pharmacies.
From 11 a.m. to 3 p.m. on June 9, the first 75 participants at each club location with a pharmacy will receive a prostate-specific antigen test to screen for accelerated PSA protein levels in the blood, which is a symptom of benign prostate enlargement and/or prostate cancer, Sam’s Club said. Additional free screenings include body mass index and blood-pressure test (limited to the first 50 participants at each location), with the total offering valued at up to $150. Sam’s Club said the May/June issue of its exclusive bimonthly wellness magazine, Healthy Living Made Simple, also highlights basic lifestyle choices to help manage men’s health.
Later this summer, Sam’s Club said it is supporting communities with free health screenings focused on healthy aging on July 14.
"Sam’s Club has provided more than one million free screenings since March 2011, and we continue to explore ways for our communities to manage their health needs with the convenience and value our members deserve," Sam’s Club SVP health and wellness Jill Turner-Mitchael said.
No comments found
Teva makes the switch from NASDAQ to NYSE
NEW YORK — Teva Pharmaceutical Industries has transferred its stock listing from NASDAQ to the New York Stock Exchange, the drug maker said Wednesday.
The company began trading on the NYSE under the ticker symbol "TEVA." On hand Wednesday to ring the Opening Bell and celebrate the company’s first day of trading on NYSE were Teva’s new president and CEO Jeremy Levin, as well as board chairman Phillip Frost, CFO Eyal Desheh, Teva Americas CEO William Marth and employees from Teva’s businesses around the world.
“We are pleased to partner with the NYSE and begin using their state of the art trading platform and market research,” Frost said. “We are joining a network of true innovators and leaders listed on the NYSE.”
Teva said it is the second-largest company to transfer its stock listing to the NYSE from NASDAQ.
No comments found